(Image générée à titre d'illustration uniquement)
Un médicament à succès est un produit pharmaceutique qui génère plus d'un milliard de dollars de ventes annuelles pour son fabricant. Ce modèle économique a historiquement guidé l'industrie pharmaceutique, en concentrant la recherche et le développement (R&D) sur les maladies chroniques courantes afin de maximiser les revenus protégés par les brevets. Ces revenus financent la R&D de nouveaux médicaments, créant ainsi un cercle vertueux d'innovation et de profits importants.
The blockbuster model became the dominant strategy for large pharmaceutical companies in the late 20th century. The model relies on developing and patenting a drug that can treat a widespread chronic condition, such as high cholesterol (e.g., Lipitor), acid reflux (e.g., Prilosec), or depression (e.g., Prozac). Once approved, the company launches a massive marketing campaign aimed at both physicians and consumers (in countries where direct-to-consumer advertising is legal). The goal is to achieve widespread prescription and capture a large market share. The drug’s patent provides a period of market exclusivity, typically 20 years from the filing date, during which the company can charge high prices without competition from generic versions. The enormous profits generated during this period are used to recoup the substantial R&D investment—often exceeding $1 billion per approved drug—and to fund the development of the next generation of potential blockbusters. However, this model faces significant challenges. The “low-hanging fruit” of common diseases has largely been addressed, making new discoveries more difficult. Increased pressure from payers (governments and insurance companies) to control costs, and the looming “patent cliff” (when patents for multiple blockbuster drugs expire around the same time), have forced the industry to reconsider this strategy. Many companies are now shifting towards developing more specialized, high-value drugs for smaller patient populations, such as orphan drugs for rare diseases or personalized cancer therapies, which can command even higher prices per patient.
En raison du trafic généré par les robots de scraping, actuellement supérieur à 40 000 par jour, ce contenu est réservé aux membres de la communauté.
> Connexion < ou > Registre < (100% gratuit) pour y accéder, ainsi qu'à tous les autres contenus et outils à accès restreint.
Modèle de médicament à succès
(si la date est inconnue ou non pertinente, par exemple « mécanique des fluides », une estimation arrondie de son émergence notable est fournie)
Les images en pleine résolution et les téléchargements sont uniquement disponibles, et 100% gratuits, pour les membres inscrits.
> Se connecter <
